RA CAPITAL MANAGEMENT, L.P. purchased $7.7M of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 1,027,722 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $7.44 ($6.91–$7.91, $7.65M total) across 3 trades over 2026-06-09 to 2026-06-11.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 11, 2026, 11:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price range, and resulting holdings after the trades.

02

Market read

Traders may treat the filing as a modest sentiment tailwind, but without new clinical/regulatory/financial catalysts it is unlikely to be a primary driver.

03

What to watch

The article lacks context on prior stake changes, valuation, and whether the buy coincided with any contemporaneous news or price dislocation.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-11; purchases executed 2026-06-09 to 2026-06-11.

Background

This is an SEC Form 4 insider transaction disclosure (RA Capital Management, L.P.) for Artiva Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management (10% owner/director) bought 1,027,722 shares of Artiva Biotherapeutics via open-market purchases totaling ~$7.65M (Form 4).

Expected impact

Near-term impact likely limited; may provide modest support to sentiment/positioning rather than drive a repricing.

Evidence & confidence

Form 4 insider/institutional buying can influence sentiment, yet the article provides no new operational/clinical/regulatory information—only transaction details and post-trade share count.

Market effects

Minimal; this is company-specific ownership activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

A large buy can be driven by pre-existing plans, liquidity needs, or portfolio rebalancing rather than a new positive thesis (note: no 10b5-1 plan is stated).

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction; RA Capital Management increased holdings via open-market buys.

  • RA Capital Management, L.P.

    Reporter on the Form 4; executed purchases totaling ~$7.65M across three trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.